A recent study has highlighted promising news for those using weight-loss drugs: glucagon-like peptide (GLP-1) receptor agonists, including the well-known medication Ozempic (semaglutide), may significantly reduce the risk of developing several types of cancer.
Overweight and obesity have been associated with an increased risk for at least 13 different cancers. GLP-1 receptor agonists, initially developed for managing type 2 diabetes, have been shown to offer additional benefits, including weight loss, improved cardiovascular health, and anti-inflammatory effects.
Researchers from Case Western Reserve University analyzed electronic health records from more than 60 healthcare organizations, examining data from over 1.65 million individuals who were prescribed GLP-1 agonists or other diabetes medications between 2005 and 2018. Their findings indicate that patients using GLP-1 agonists experienced a notably lower risk of developing 10 out of 13 obesity-related cancers compared to those receiving insulin therapy.
Key findings include a 65% reduction in the risk of gallbladder cancer, a 53% reduction in liver cancer, a 48% reduction in ovarian cancer, and a 46% reduction in colorectal cancer among GLP-1 agonist users. These reductions in cancer risk were comparable to those achieved through bariatric surgery or intensive lifestyle interventions that include diet and exercise.
However, the study did not find a significant difference in cancer risk reduction when comparing GLP-1 agonists to metformin, another diabetes medication known for its anti-inflammatory properties and potential cancer risk-lowering effects.
The study authors emphasize that while these results are encouraging, further long-term research is needed to confirm the cancer-preventive benefits of GLP-1 agonists. They also recommend evaluating these drugs for their potential role in secondary cancer prevention to help delay recurrence.
In summary, GLP-1 receptor agonists not only aid in weight management and diabetes control but may also offer significant cancer risk reduction benefits, though additional studies are necessary to fully understand and validate these findings.
